VolitionRx Secures $1.2 Million Through Direct Offering
VolitionRx Limited (NYSE American: VNRX), a prominent player in the epigenetics field, has recently announced a significant financing round. This funding, amounting to $1.2 million, is a registered direct offering that underscores the company's commitment to enhancing healthcare through innovative solutions.
Details of the Offering
In this latest offering, VolitionRx has entered into agreements to sell a total of 156,250 shares of its common stock directly to certain directors and executive officers, collectively referred to as the "Insiders." These shares are priced at $0.64 each. Meanwhile, an additional 1,734,375 shares are being sold alongside purchase warrants to existing stockholders, again at the same price per share. Each warrant allows for the purchase of an additional share at an exercise price of $0.768. These warrants can be exercised immediately and will expire five years from their issuance date.
Offering Timeline and Proceeds
This offering is anticipated to close promptly, pending the satisfaction of customary closing conditions. With gross proceeds expected to reach $1.21 million before costs, the company is gearing up to utilize the funds effectively. Should the accompanying warrants be fully exercised, the total gross proceeds could rise to approximately $1.3 million. VolitionRx plans to channel these funds towards ongoing research, product development, clinical studies, and strategic acquisitions that align with its mission to improve disease detection.
Why This Matters
The funding from this offering is crucial for VolitionRx as it continues its journey in the epigenetics sector. The company is dedicated to advancing technologies that can lead to earlier disease detection and monitoring, a vital factor in improving patient outcomes. This funding not only supports current projects but also positions Volition for future advancements that could significantly impact both human and animal health.
VolitionRx's Commitment to Innovation
With a presence in various regions including Belgium and the U.S., VolitionRx is tapping into its extensive research capabilities to create cost-effective blood tests. These tests aim to facilitate the early detection of conditions such as certain cancers and diseases linked to NETosis. The overall goal is to enhance the quality of life for patients through innovative healthcare solutions.
Media and Investor Relations
For those interested in media inquiries, Louise Batchelor is available for comment and can be reached through the company's official channels. Additionally, investor relations are managed by Jeremy Feffer of LifeSci Advisors, who is on hand to assist with any investor-focused questions.
About Volition
VolitionRx is a global company committed to the groundbreaking field of epigenetics. With a keen focus on saving lives through earlier disease detection, the company strives to improve health outcomes for all. By commercializing user-friendly blood tests, it aims to provide significant benefits in monitoring and detecting various health conditions. Early intervention and effective monitoring serve as cornerstones for changing the lives of those afflicted with challenging health issues.
Frequently Asked Questions
What is the purpose of VolitionRx's recent offering?
The recent offering aims to raise funds for research, product development, and strategic acquisitions to boost health solutions in disease detection.
How much money is VolitionRx expecting to raise?
VolitionRx anticipates raising around $1.2 million from the offering, with potential additional funds from exercised warrants.
Who are the purchasers of the common stock?
Purchasers include certain directors, executive officers, and existing stockholders who support the company's initiatives.
What type of products is VolitionRx focused on developing?
VolitionRx focuses on developing blood tests for early disease detection, including various cancers and NETosis-related conditions.
Where does VolitionRx carry out its research activities?
Research activities are primarily based in Belgium, with additional offices in the U.S. and London, indicating a strong international presence.
